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POLICY AND PRACTICE UPDATES    
 
An Evaluation of Beijing’s Medical Insurance Payment Reforms  
Source: 21st Century Economic Report 2011-8-19 
http://www.21cbh.com/HTML/2011-8-19/wMMDY5XzM1ODQwMQ.html  
 
The Diagnosis-Related Groups (DRGs)-based payment system has long been proposed as a solution 
to high medical costs. This prospective payment system allocates payments according to related 
diagnosis groups that are established according to similar patient age, disease diagnosis, disease 
comorbidities, disease severity, treatment methods, and other factors.  
 
After years of research and testing, Beijing will lead the way by piloting this new system in six 
hospitals beginning Aug 1st, with 650 locally identified DRGs. Under the new system, if hospitals 
charge more than the set price for a certain disease, they will be responsible for the difference. This 
new reality will exert outside pressure for hospitals to reform their organization and management 
systems. 
 
There have been high expectations for DRGs-based payment system to reduce ever increasing 
medical costs. As early as 1993, hospital management research in Beijing had shown feasibility of 
DRGs system, but nothing came from the research due to infrastructure limitations, such as lack of a 
reliable computer information system. Since then, DGRs-based payment system has been widely 
adopted in many countries with success. Currently in China, there is still reluctance to implement 
the system, partly due to worries about resistance from medical professionals. 
 
“Implementation of DRG will not affect doctors’ day-to-day work,” said Mu Hu, director of the DRG 
Beijing project technical team, “because this is just a new hospital management system with little 
impact on how doctors diagnose or treat their patients. They only need to get use to a new 
management system.” 
 
As to the worry that DRG system might reduce hospital service quality, Mu Hu also disagrees. “By 
using this system, all medical services could be clearly viewed and compared across hospitals. It will 
be obvious who provides better or worse services.” 
 
For DRGs-based payment system to reach its full potential in cost reduction, other supporting 
systems and policies need to be in place, and Beijing’s foray into payment system reform is 
complemented with three supporting policies. First, medical insurance foundation will establish a 
pre-pay system to distribute funds to the six pilot hospitals. Distribution for the first month will be 
based on the case load in these hospitals during same time period in 2010. Subsequent distributions 
will be based on hospital performance in the previous months. Second, pilot hospitals will be able to 
independently purchase medicine and medical supplies, but they must do so at a price lower than 
or comparable to their previous records. Third, attending doctors will be responsible for their own 
cases, in direct contrast to the existing system where departments are responsible for everything. 
 
Piloting Urban-Rural Medical Insurance Integration: The New Rural Cooperative Medical Scheme to 
Be Administered by Ministry of Labor and Social Security  
Source: 21st Century Economic Report 2011-9-14 
http://www.21cbh.com/HTML/2011-9-14/5OMDY5XzM2NDQ5OA.html 
 
In August 2011, the city of Kunming in Yunnan Province transitioned management of the New Rural 
Cooperative Medical Scheme to the Ministry of Labor and Social Security, achieving unified 
management of insurances for residents and workers in either rural or urban settings. Together with 
other regions that implemented the same measure, such as Ningxia, Chengdu and Wenzhou, 






According to Social Insurance Law implemented in July 2011, State Council will issue detailed 
blueprints for how to integrate urban-rural medical insurances. However, no document has been 
produced to date, and reform has been carried out at localities under their own initiative. 
Currently, the Ministry of Health still manages the New Rural Cooperative Medical Insurance Plan, 
while the Ministry of Labor and Social Security is managing urban residents and worker insurances. 
This dual management presents an obstacle to human resource movement between rural and 
urban areas, also urbanization. To truly integrate urban and rural insurances, all related agencies 
need to be combined and form a single responsible agency, to streamline human and material 
resources management and distribution.  
 
The “Obsolete” Essential Drug Policy: Some Provinces Reauthorize Non-listed Drugs 
Source: 21st Century Economic Report 2011-9-15 
http://www.21cbh.com/HTML/2011-9-15/1NMDY5XzM2NDg1NA.html 
 
While the central government continues to optimize the Essential Drug System, some provinces 
provide tacit approval for non-listed drugs to reenter the primary medical care system. 
 
Anhui, the first province to adopt the Essential Drug System, recently allowed health care system to 
add drugs from New Rural Cooperative Medical Care and Medical Insurance catalogue, but not 
exceeding 15% of total expenditure. Shandong, Zhejiang and Jiangsu have already added non-
listed drugs to their health care systems. 
 
The Essential Drug List was introduced in August 2009 and instructed primary health care systems to 
equip and utilize all 307 types of essential drugs listed. Ideally, only the listed drugs should be used. 
However, since its introduction, there has been continued feedback that the list could not meet 
local demands. According to a hospital administrator in Jiangsu Province, one secondary hospital 
utilizes 600 to 1000 types of medicine daily. If they strictly follow the Essential Drug System, some 
specialty departments could not continue their functions.  
 
Even with the added drugs, the demands of primary health care system still could not be met, 
resulting in loss of patients and thus revenue. Many field experts suggest that local health care 
systems should be allowed to add non-listed drugs as their financial situations permit.  
 
The Conundrum of “Zero Markup” 
Source: Finance 2011-9-13 
http://magazine.caijing.com.cn/2011-09-13/110857233.html 
 
During a recent conference organized by the Ministry of Public Health, the “Zero Markup” policy 
was called into question. Several provincial and city health departments requested modifications 
to the existing essential drug policy, including stopping “Zero Markup” practice.  
 
The essential drug policy is a systematic approach that regulates production, wholesale bidding, 
distribution, sales, and patient use. Other than wholesale bidding, the “Zero Markup” sales strategy 
is the most essential component and could highly impact implementation of the entire policy. 
However, without an effective government reimbursement system, many primary care facilities 
sustained significant financial losses.  
 
In Anhui, some primary care facilities separated their services into essential and specialized. On the 
essential service side, only drugs on the Essential Drug List are utilized with zero markup, while on the 
specialized side, additional drugs are used with markup, to increase revenue. In Beijing, “Zero 
Markup” was only strictly implemented for half a year. Facing significant patient and revenue loss, 
the policy was relaxed to include non-listed drugs with markup. If current policy is continued without 




Hengpeng Zhu, a researcher from the Chinese Academy of Social Sciences, Institute of Economics, 
suggested that the markup regulation could be relaxed to allow further price negotiations between 
local health care system and drug companies. A price ceiling could be set using provincial 
negotiations as standard, but allow primary health care systems to generate revenue from drug 
sales. He pointed out that “internationally, countries that implemented zero markup policy do not 
have comprehensive medical insurance. Since we already have medical insurance, there is no 
need to establish an essential drug policy. Based on past international experience, medical 
expense reduction could be achieved through reforming insurance payment system.” 
Competitions between public hospitals, drug stores, and private hospitals will help ensure lower 
drug prices. 
 
Ministry of Health Plans to Adjust the Essential Drug List: Expanding the Regular Used Drug List 
Source: Economic Observer 2011-10-31 
http://epaper.xplus.com/papers/jjgcb/20111031/n17.shtml  
 
The Ministry of Health will start evaluating implementation of the Essential Drug List by end of 2011, in 
preparation for its modification in early 2012.  
 
The Essential Drug List was released in August 2009 for primary care setting, with the intention of 
continued modification and eventual implementation for all public medical facilities. The list 
contained 307 drugs, and if patients utilize only these drugs, they could receive 100% 
reimbursement from medical insurance. However, as coverage of the policy increased, problems 
also surfaced.  
 
The main issue is that the Essential Drug List could not satisfy patient demand. In many regions of 
China, especially regions with higher levels of income, additional drugs were added to the list to 
meet the demand. In order to remedy the situation, the list needs to be updated. . According to 
Zheng Hong, an official from the Ministry of Health, the new list will better accommodate clinical 
needs, and put more emphasis on treatment and prevention of major diseases and chronic 
diseases.  
 
Foreign Pharmaceuticals “Got Lost” in China’s Health Reforms: Norvatis Admits Reduced Profit 
Source: 21st Century Economic Report 2011-11-2 
http://www.21cbh.com/HTML/2011-11-2/wNMDcyXzM3NjMwNA.html  
 
2011 marks the third year of China’s Health Reform, and foreign pharmaceutical companies started 
to see their profitability being eroded. On October 31, 2011, Lars Rebien Sorensen, CEO of Norvatis, 
revealed that even though their company would maintain a 15% growth rate for the entire year, 
their profit was reduced in the third quarter, due to influence of China’s Health Reform and the 
medicine pricing policy. Norvatis is the leading manufacturer of insulin, occupying over 60% of 
world market and 63% of Chinese market.  
 
The China’s Health Reform is a double-edged sword for Norvatis. The new bidding system on 
essential drugs helped Norvatis expanding its market share; however, the reform also decreased 
drug retail price, and the latter outweighs the former. A good example is the company’s main 
product, insulin. Since September 1 2011, every province in China adjusted price of insulin, bringing 
the price of this brand medicine close to generic ones, nearly canceling any profitability. 
Additionally, it has become increasingly difficult to obtain approval for newly developed medicine. 
Reduced profitability on older drugs, coupled with limited approval for new drugs, is slowly eroding 
foreign pharmaceutical companies’ market share in China.  
 
  
